| Description |
Suvratoxumab (MEDI4893) is a long-acting, high-affinity humanized anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394)[1][2][3].
|
| Related Catalog |
|
| Target |
α-toxin of S. aureus[1][2][3].
|
| In Vivo |
Suvratoxumab (5, 15, 45 mg/kg; i.p.; single) 可提高免疫功能低下的小鼠肺炎模型的存活率[1]。 Suvratoxumab (15 mg/kg; i.p.; single) 可减少小鼠的肺损伤并增加巨噬细胞的吞噬作用[1]。 Suvratoxumab (15 mg/kg; i.p.; single) 可增强抗生素（万古霉素或利奈唑胺）治疗小鼠的有效性[1]。 Animal Model: Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1]. Dosage: 5, 15, 45 mg/kg Administration: Intraperitoneal injection; single Result: Resulted in dose-dependent increases in survival rates and reductions in bacterial CFU. Animal Model: Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1]. Dosage: 15 mg/kg Administration: Intraperitoneal injection; single Result: Prophylaxis protected the lungs of S. aureus-infected immunocompromised mice from α toxin-mediated damage.
|
| References |
[1]. Hua L, et al. MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model. Antimicrob Agents Chemother. 2015 Aug;59(8):4526-32. [2]. Yu XQ, et al. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e01020-16. [3]. Oganesyan V, et al. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80.
|
